BIIB vs INSM
BIIB: A pioneer in neuroscience and immunology, Biogen is a major biotechnology company focused on addressing high-unmet medical needs in complex diseases like Alzheimer’s, Multiple Sclerosis, and SMA. INSM: A biopharmaceutical company with approved rare respiratory therapies (ARIKAYCE for MAC lung disease, BRINSUPRI for bronchiectasis) and a pipeline in respiratory, immunology, and neurological rare diseases.
Side-by-side fundamentals
| Metric | BIIB | INSM | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $200.14 | $104.73 | |
| Market cap as of 2026-07-31 | $30.3B | $21.6B | |
| P/E as of 2026-07-31 | 22.09 | n/a | |
| PEG as of 2026-07-31 | 10.24 | n/a | |
| Net margin as of 2026-07-31 | +13.8% | -144.4% | BIIB higher |
| Gross margin as of 2026-07-31 | +75.5% | +81.8% | INSM higher |
| Operating margin as of 2026-07-31 | +17.5% | -140.6% | BIIB higher |
| ROE as of 2026-07-31 | +7.5% | -130.1% | BIIB higher |
| ROA as of 2026-07-31 | +4.7% | -51.6% | BIIB higher |
| Debt / equity as of 2026-07-31 | 0.34 | 1.03 | BIIB lower |
| Revenue growth (YoY) as of 2026-07-31 | +1.2% | +115.1% | INSM higher |
| Revenue CAGR (3y) SEC XBRL | -0.9% | +35.2% | INSM higher |
| Beta as of 2026-07-31 | 0.16 | 0.81 | |
| 1-year return as of 2026-07-27 close | +52.2% | +0.8% | BIIB higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.